Turning Point Benefit Group’s Repligen RGEN Stock Holding History

Turning Point Benefit Group’s Portfolio RGEN Stock Details RGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1	Closed	-$145	–	896
2025 Q3	$145	Buy	+1	New	+$121	﹤0.01%	683

Other funds holding RGEN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Turning Point Benefit Group's RGEN Position: Q4 2025 in Review

Turning Point Benefit Group sold out of Repligen (RGEN) in Q4 2025, closing a stake of 1 share — an estimated $145 sold.

Turning Point Benefit Group first reported a position in RGEN in Q3 2025 and held it in 1 quarter. The position peaked at $145 in Q3 2025. 474 funds tracked by Wall St. Rank hold RGEN as of Q4 2025.

Turning Point Benefit Group reported no remaining Repligen position as of Q4 2025 after selling out during the quarter.
Turning Point Benefit Group sold 1 Repligen share in Q4 2025, an estimated $145.
Turning Point Benefit Group first reported a position in Repligen in Q3 2025 and held it in 1 quarter.
Turning Point Benefit Group's Repligen position peaked at $145 in Q3 2025.
474 funds tracked by Wall St. Rank held Repligen as of Q4 2025.

Based on Turning Point Benefit Group's 13F filing for Q4 2025, filed 30 Jan 2026.